In the first quarter, Tianqi Lithium Corporation (09696) reported a net profit attributable to equity shareholders of approximately 1.876 billion yuan, an increase of about 16.99 times year-on-year.
Tianqi Lithium (09696) announced that in the first quarter of 2026, the operating income was approximately 5.128 billion yuan, a year-on-year increase of 98.44%; the net profit attributable to the shareholders of the listed company was approximately 1.876 billion yuan, a year-on-year increase of about 16.99 times; basic earnings per share was 1.12 yuan.
Tianqi Lithium Corporation (09696) announces that in the first quarter of 2026, its operating income is approximately 5.128 billion yuan, a year-on-year increase of 98.44%; the net profit attributable to shareholders of the listed company is approximately 1.876 billion yuan, a year-on-year increase of about 16.99 times; basic earnings per share is 1.12 yuan.
The announcement stated that the main reasons for the increase in net profit are: 1) Benefiting from the development of new energy industry and growth in downstream demand, the average selling price of the company's main lithium products during this reporting period has significantly increased compared to the same period last year, leading to a substantial increase in operating income and gross profit compared to the same period last year; 2) According to Bloomberg's forecast data, SQM's performance in the first quarter of 2026 is expected to increase significantly year-on-year, leading to an increase in the investment income from the associated company recognized by the company during this reporting period compared to the same period last year.
Related Articles

J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.

UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.

LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.
J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.

UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.

LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.






